cro.directory
← Compare landing

ICON plc vs Tigermed

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/iconplc/tigermedgrp

CategoryICON plcTigermed
Listed sitecrocro
SummaryICON is a world-leading clinical research organization providing outsourced services across the full clinical trial lifecycle, from early phase through commercialization, to pharmaceutical, biotechnology, and medical device companies.Leading global CRO providing end-to-end clinical trial services, preclinical development, medical device and IVD trials, regulatory affairs, and real-world evidence studies across 180+ offices serving 4,000+ customers.
Services
  • Phase I Clinical Trials
  • Phase II Clinical Trials
  • Phase III Clinical Trials
  • Phase IV / Post-Marketing
  • Clinical Operations
  • Clinical Trial Services
  • Clinical Imaging Core Lab
  • Central Laboratory Services
  • Data Management & eClinical
  • Biostatistics & Statistical Programming
  • Medical Writing
  • Pharmacovigilance & Drug Safety
  • Regulatory Affairs
  • US FDA Regulatory Strategy
  • EU EMA Regulatory Strategy
  • Flow Cytometry Services
  • Bioanalysis
  • Translational Research
  • Biomarker Assays
  • Immunogenicity Assays (ADA / NAb)
  • Ligand-Binding Bioanalysis (Large Molecule)
  • LC-MS Bioanalysis (Small Molecule)
  • Cardiovascular & Metabolic Specialty Services
  • CNS Specialty Services
  • Oncology Specialty Services
  • Immunology & Inflammation Services
  • Companion Diagnostics Development
  • Japan PMDA Regulatory Strategy
  • China NMPA Regulatory Strategy
  • Phase I Clinical Trials
  • Phase II Clinical Trials
  • Phase III Clinical Trials
  • Phase IV / Post-Marketing
  • Clinical Operations
  • Clinical Trial Services
  • Clinical Imaging Core Lab
  • Central Laboratory Services
  • Medical Writing
  • Pharmacovigilance & Drug Safety
  • Biostatistics & Statistical Programming
  • Data Management & eClinical
  • Regulatory Affairs
  • US FDA Regulatory Strategy
  • EU EMA Regulatory Strategy
  • China NMPA Regulatory Strategy
  • Japan PMDA Regulatory Strategy
  • Device & Combination Product Services
  • Translational Research
  • GLP Toxicology
  • In Vitro ADME / DMPK
  • In Vitro Pharmacology
  • Preclinical In Vitro Studies
  • In Vivo PK / PD Studies
  • In Vivo Efficacy Models
  • Preclinical In Vivo Studies
  • Bioanalysis
  • LC-MS Bioanalysis (Small Molecule)
  • Ligand-Binding Bioanalysis (Large Molecule)
  • Medicinal Chemistry
  • High-Throughput Screening
  • Oncology Specialty Services
  • Cardiovascular & Metabolic Specialty Services
  • CNS Specialty Services
  • Immunology & Inflammation Services
  • Virology Services
  • Microbiology Services
Modalities
  • Small Molecule
  • Biologics (Monoclonal Antibodies)
  • Biologics (Other)
  • Cell Therapy
  • Gene Therapy
  • Vaccine
  • Small Molecule
  • Biologics (Monoclonal Antibodies)
  • Biologics (Other)
  • Vaccine
  • Cell Therapy
  • Gene Therapy
  • Radiopharmaceutical
  • Oligonucleotide
  • Peptide
Indications
  • Cardiovascular
  • Neurology
  • Immunology
  • Oncology
  • Infectious Disease
  • Metabolic
  • Rare Disease
  • Women's Health
  • Ophthalmology
  • Oncology
  • Cardiovascular
  • Neurology
  • Immunology
  • Infectious Disease
  • Rare Disease
  • Metabolic
  • Ophthalmology
  • Gastroenterology
  • Respiratory
Locations
  • Headquarters, Dublin, Ireland
  • Belgium, Belgium, Belgium
  • Bulgaria, Bulgaria, Bulgaria
  • Germany, Germany, Germany
  • Hungary, Hungary, Hungary
  • Italy, Italy, Italy
  • Netherlands, Netherlands, Netherlands
  • Poland, Poland, Poland
  • Romania, Romania, Romania
  • Slovakia, Slovakia, Slovakia
  • South Africa, South Africa, South Africa
  • Spain, Spain, Spain
  • Türkiye, Türkiye, Türkiye
  • United Kingdom, United Kingdom, United Kingdom
  • Australia, Australia, Australia
  • China, China, China
  • India, India, India
  • Japan, Japan, Japan
  • Korea, Korea, Korea
  • Malaysia, Malaysia, Malaysia
  • Taiwan, Taiwan, Taiwan
  • Argentina, Argentina, Argentina
  • Brazil, Brazil, Brazil
  • Chile, Chile, Chile
  • Colombia, Colombia, Colombia
  • Mexico, Mexico, Mexico
  • Belgium, Belgium, Belgium
  • Bulgaria, Bulgaria, Bulgaria
  • Germany, Germany, Germany
  • Hungary, Hungary, Hungary
  • Italy, Italy, Italy
  • Netherlands, Netherlands, Netherlands
  • Poland, Poland, Poland
  • Romania, Romania, Romania
  • Slovakia, Slovakia, Slovakia
  • South Africa, South Africa, South Africa
  • Spain, Spain, Spain
  • Türkiye, Türkiye, Türkiye
  • United Kingdom, United Kingdom, United Kingdom
  • Australia, Australia, Australia
  • China, China, China
  • India, India, India
  • Japan, Japan, Japan
  • Korea, Korea, Korea
  • Malaysia, Malaysia, Malaysia
  • Taiwan, Taiwan, Taiwan
  • Argentina, Argentina, Argentina
  • Brazil, Brazil, Brazil
  • Chile, Chile, Chile
  • Colombia, Colombia, Colombia
  • Mexico, Mexico, Mexico
  • United States, United States, United States
  • Headquarters, Hangzhou, Zhejiang, China
  • Global Offices, Multiple, Global, Multiple (180+ locations across 5 continents)
CertificationsData not yet provided.Data not yet provided.
ReviewsReview summary appears after site-level review signal gate opens.Review summary appears after site-level review signal gate opens.